CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms
Status:
Active, not recruiting
Trial end date:
2021-11-16
Target enrollment:
Participant gender:
Summary
The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical
trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients
infected with SARS-CoV-2.
The specific objectives are to assess whether, in patients with mild and moderate forms of
SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of:
i) decrease viral load; ii) modify inflammatory parameters, such as cytokines, measured from
serum; iii) reduce clinical and emotional symptoms through daily clinical evaluation; iv)
improve sleep; v) reduce hospitalization and worsen the severity of the disease; v) Monitor
the possible adverse effects of CBD use in these patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Sao Paulo
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico Fundação de Amparo à Pesquisa do Estado de São Paulo